Back to results
US 9,040,498 B2Granted
1,2,3-Triazolyl purine derivatives
AssigneeResearch Foundation of the City University of New York
InventorMahesh K. Lakshman
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections. An example of a 1,2,3-triazolyl purine derivative of the invention is
Claims35
A compound having Formula I,
- wherein:
- R1 represents an alkyl, an aryl, —SiR4, —SnR5, —B(R4)2, —B(OH)2, an amide, an imide, or an organometallic;
- R2 and R3 independently represent N, CH, or CR6;
- R4 independently represents —R5 or —OR5;
- R5, R7 and R8, independently of each other and independently at each position, represent alkyl, cycloalkyl, or aryl;
- R7 and R8 independently, may be combined to represent a heterocyclic alkyl or a heterocyclic aryl;
- R6 independently represents an alkyl or an aryl;
- Y represents H, an alkyl, an aryl, or a saccharide moiety;
- alkyl groups are branched or unbranched, saturated or unsaturated, and have 1-18 carbon atoms in their longest chain;
- cycloalkyl groups are carbocyclic or heterocyclic, fused or unfused, non-aromatic ring systems having a total of 5-16 ring members including substituent rings;
- aryl groups are carbocyclic or heterocyclic;
- carbocyclic aryl groups are fused or unfused ring systems having a total of 6-16 ring members including substituent rings;
- heterocyclic aryl groups are fused or unfused ring systems having a total of 5-16 ring members including substituent rings;
- halo substituents are fluoro, chloro, bromo, or iodo;
- each alkyl, cycloalkyl, and aryl, independently, may be unsubstituted or substituted with one or more substituent at any position;
- alkyl substituents are halo, hydroxyl, —OR5, —SR5, —S(O)R4, —S(O)2R4, —NH2, —NHR5, —NR7R8, cycloalkyl, or aryl;
- cycloalkyl substituents are halo, hydroxyl, —OR5, —SR5, —NH2, —NHR5, —NR7R8, alkyl, cycloalkyl, or aryl;
- aryl substituents are halo, hydroxyl, —OR5, —SR5, —NH2, —NHR5, —NR7R8, —CN, alkyl, cycloalkyl, aryl, nitro, or carboxyl;
- and
- heterocyclic alkyl and heterocyclic aryl have at least one heteroatom selected from the group consisting of oxygen, nitrogen and sulfur.
17 more elements
A compound having Formula II,
- wherein:
- R1 represents an alkyl, an aryl, —SiR4, —SnR5, —B(R4)2, —B(OH)2, an amide, an imide, or an organometallic;
- R2 and R3 independently represent N, CH, or CR6;
- X represents —OR9, —SR9, or —NR9R10;
- Y represents H, an alkyl, an aryl, or a saccharide moiety;
- R4 independently represents —R5 or —OR5;
- R5, R7 and R8, independently of each other and independently at each position, represent alkyl, cycloalkyl, or aryl;
- and
- R6 independently represents an alkyl or an aryl;
- R9 and R10 independently represent H, an alkyl, or an aryl;
- R7 and R8, R9 and R10 independently, may be combined to represent a heterocyclic alkyl or a heterocyclic aryl;
- alkyl groups are branched or unbranched, saturated or unsaturated, and have 1-18 carbon atoms in their longest chain;
- cycloalkyl groups are carbocyclic or heterocyclic, fused or unfused, non-aromatic ring systems having a total of 5-16 ring members including substituent rings;
- aryl groups are carbocyclic or heterocyclic;
- carbocyclic aryl groups are fused or unfused ring systems having a total of 6-16 ring members including substituent rings;
- heterocyclic aryl groups are fused or unfused ring systems having a total of 5-16 ring members including substituent rings;
- halo substituents are fluoro, chloro, bromo, or iodo;
- each alkyl, cycloalkyl, and aryl, independently, may be unsubstituted or substituted with one or more substituent at any position;
- alkyl substituents are halo, hydroxyl, —OR5, —SR5, —S(O)R4, —S(O)2R4, —NH2, —NHR5, —NR7R8, cycloalkyl, or aryl;
- cycloalkyl substituents are halo, hydroxyl, —OR5, —SR5, —NH2, —NHR5, —NR7R8, alkyl, cycloalkyl, or aryl;
- aryl substituents are halo, hydroxyl, —OR5, —SR5, —NH2, —NHR5, —NR7R8, —CN, alkyl, cycloalkyl, aryl, nitro, or carboxyl;
- and
- heterocyclic alkyl and heterocyclic aryl have at least one heteroatom selected from the group consisting of oxygen, nitrogen and sulfur.
20 more elements
A compound having Formula III,
- wherein:
- R9, R10, R12, R13, R14, R15, R16, and R17 independently represent N or CR11;
- R11 independently represents —R18, —OR19, —SR19, —N(R18)2, R18C(O)—, nitro, or halo;
- R18 independently represents H, an alkyl group, or an aryl;
- R19 independently represents R18 or a protecting group;
- Y represents R18 or a saccharide moiety;
- alkyl groups are branched or unbranched, saturated or unsaturated, and have 1-18 carbon atoms in their longest chain;
- cycloalkyl groups are carbocyclic or heterocyclic, fused or unfused, non-aromatic ring systems having a total of 5-16 ring members including substituent rings;
- aryl groups are carbocyclic or heterocyclic;
- carbocyclic aryl groups are fused or unfused ring systems having a total of 6-16 ring members including substituent rings;
- heterocyclic aryl groups are fused or unfused ring systems having a total of 5-16 ring members including substituent rings;
- halo substituents are fluoro, chloro, bromo, or iodo;
- each alkyl, cycloalkyl, and aryl, independently, may be unsubstituted or substituted with one or more substituent at any position;
- alkyl substituents are halo, hydroxyl, —OR5, —SR5, —S(O)R4, —S(O)2R4, —NH2, —NHR5, —NR7R8, cycloalkyl, or aryl;
- cycloalkyl substituents are halo, hydroxyl, —OR5, —SR5, —NH2, —NHR5, —NR7R8, alkyl, cycloalkyl, or aryl;
- aryl substituents are halo, hydroxyl, —OR5, —SR5, —NH2, —NHR5, —NR7R8, —CN, alkyl, cycloalkyl, aryl, nitro, or carboxyl;
- and
- heterocyclic alkyl and heterocyclic aryl have at least one heteroatom selected from the group consisting of oxygen, nitrogen and sulfur;
- R4 independently represents —R5 or —OR5;
- R5, R7 and R8, independently of each other and independently at each position, represent alkyl, cycloalkyl, or aryl;
- and
- R7 and R8 independently, may be combined to represent a heterocyclic alkyl or a heterocyclic aryl.
19 more elements
A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of Formula I or a compound below:
Dependencies are inferred from the claim text.